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Perspective: This is the first large-scale clinical trial to com-
pare automatic remote HM of ICDs to conventional
follow-up in a device clinic. The major advantages of HM
over conventional clinic evaluations are that it does not
depend on patient compliance and it allows much earlier
detection of a system malfunction.   
Summary written by: Fred Morady, MD
Dyssynchrony Indices to Predict Response to
Cardiac Resynchronization Therapy: 
A Comprehensive, Prospective Single-Center Study
Miyazaki C, Redfield MM, Powell BD, et al.
Circ Heart Fail 2010;Jul 20:[Epub ahead of print].
Study Question: Do echocardiographic indices of dyssynchrony
predict reverse remodeling or clinical response to cardiac
resynchronization therapy (CRT)?  
Methods: A total of 184 patients with heart failure in whom
CRT was anticipated were prospectively enrolled; of these,
131 patients with wide QRS and left ventricular (LV) ejec-
tion fraction <35% had 6-month follow-up after CRT
implantation. The utility of 14 dyssynchrony indices was
evaluated using M-mode, tissue velocity and tissue Doppler
strain, 2D speckle strain (65-86%), 3D echocardiography
(79%), and timing intervals (98%).
Results: Reverse remodeling (end-systolic volume [ESV]
reduction ≥15%) occurred in 55%, and more frequently in
nonischemic (71%) than ischemic patients (42%, p = 0.002).
Overall, only M-mode, tissue Doppler strain, and total isovo-
lumic time (IVT) had a receiver operating characteristic area
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Arrhythmias
Efficacy and Safety of Automatic Remote Monitoring
for Implantable Cardioverter-Defibrillator Follow-Up.
The Lumos-T Safely Reduces Routine Office Device
Follow-Up (TRUST) Trial
Varma N, Epstein AE, Irimpen A, Schweikert R, Love C, on behalf of
the TRUST Investigators.
Circulation 2010;122:325–332.
Study Question: What is the incremental value of automatic
remote monitoring compared to conventional device clinic
follow-up in patients with implantable cardioverter-defibril-
lators (ICDs)?
Methods: A total of 1,339 ICD recipients (mean age 63 years)
were randomly assigned to remote home monitoring (HM)
with automatic daily transmission of ICD data (n = 908) or to
conventional device interrogation in clinic every 3 months (n
= 431). The 1° efficacy endpoint was the number of in-office
device evaluations, and the 1° safety endpoint was major
adverse events.
Results: Mean follow-up was 1 year. The mean number of in-
office device evaluations was significantly lower in the HM
group than the conventional group (2.1 vs. 3.8). A major
adverse event occurred in 10% of patients, with no difference
between groups. Median time to evaluation of arrhythmic
events was <2 days in the HM group compared to 36 days in
the conventional group.
Conclusions: Remote HM of ICDs allows the early detection
of ICD events without compromising safety.
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6.4%) and asymptomatic patients (4.5% vs. 2.7%). Beyond
the periprocedural period, there was no difference in the
incidences of ipsilateral stroke.
Conclusions: There is no difference between CAS and CEA
with respect to the composite endpoint. CAS is associated
with a higher risk of periprocedural stroke and a lower risk
of MI compared with CEA.
Perspective: The results of this trial are consistent with a recent
meta-analysis of all published prior data (Meier P, et al., BMJ
2010), and show that CAS carries an increased risk of
periprocedural stroke, a lower risk of MI, and no difference in
long-term outcome compared with CEA. This suggests that
the two therapies should be viewed as complementary, and
efforts should be made to reduce the periprocedural complica-
tions unique to each procedure (stroke with CAS and MI
with CEA).  
Summary written by: Hitinder S. Gurm, MBBS
Use of Angiotensin Converting Enzyme Inhibitors
Is Associated With Increased Growth Rate of
Abdominal Aortic Aneurysms 
Sweeting MJ, Thompson SG, Brown LC, Greenhalgh RM, Powell JT.
J Vasc Surg 2010;52:1–4.
Study Question: A recent  large Canadian study has suggested
that patients taking angiotensin-converting enzyme (ACE)
inhibitors are less likely to present with a ruptured abdominal
aortic aneurysm (AAA). Is concurrent use of ACE inhibitors
associated with a reduction in aneurysm growth rates?
Methods: This prospective cohort study analyzed data from a
subset of patients enrolled or considered for inclusion in the
UK Small Aneurysm Trial. From 1991-1995, 1,701 patients
with aneurysms 4-5.5 cm in diameter in the study had at
least two ultrasound measurements of aneurysm diameter
and baseline drug prescription data available. The effects of
antihypertensive medications on aneurysm growth rates were
estimated by mixed effects linear growth modeling.
Results: A total of 1,743 individuals met eligibility require-
ments for inclusion. Only 1,701 patients had baseline
prescription data recorded providing 3,289 person-years
(mean 1.9 years) of follow-up and 8,979 (mean 5.3 measure-
ments, mean diameter 4.3 cm) AAA measurements.
Baseline patients taking ACE inhibitors were more likely to
have larger aneurysms, ischemic heart disease, lower ankle-
brachial indices, history of hypertension, and take statins or
antiplatelet medications. Patients on ACE inhibitors had on
average a 0.63 mm/yr (p = 0.009) increase in AAA diameter
compared to patients not on ACE inhibitors (average
growth rates of 3.37 vs. 2.74 mm/yr, respectively). Use of
other antihypertensives (including beta-blockers) and statins
did not significantly change AAA growth rates. 
under the curve (AUC) greater than the line of no informa-
tion, but none of these were strongly predictive of reverse
remodeling (AUC 0.63-0.71). In nonischemic cardiomyopa-
thy, no dyssynchrony index predicted reverse remodeling. In
ischemic cardiomyopathy, M-mode (AUC = 0.67), tissue
Doppler strain (AUC = 0.79), and IVT (AUC = 0.76) derived
indices predicted reverse remodeling (p < 0.05 for all),
although the incremental value was modest.
Conclusions: These findings are consistent with the Predictors
of Response to CRT (PROSPECT) study, and do not sup-
port use of echocardiographic dyssynchrony indices to guide
use of CRT.
Perspective: CRT is associated with symptomatic and mortal-
ity benefits. However, 20-30% of patients are
‘nonresponders,’ in whom CRT fails to result in benefit
despite appropriate indications for therapy. This and other
studies have shown that echocardiography/Doppler tech-
niques do not reliably identify responders to CRT. Thus, it
appears reasonable to conclude that decisions to use CRT
should not be based on currently available echocardio-
graphic/Doppler variables.  
Summary written by: David S. Bach, MD
Cardiovascular Surgery
Stenting Versus Endarterectomy for Treatment of
Carotid-Artery Stenosis
Brott TG, Hobson RW 2nd, Howard G, et al., on behalf of the
CREST Investigators.
N Engl J Med 2010;363:11–23.
Study Question: What is the safety and efficacy of carotid
artery stenting (CAS) compared with carotid endarterec-
tomy (CEA) in average risk patients?
Methods: The CREST investigators randomized 2,502
patients with symptomatic or asymptomatic carotid stenosis
to undergo CAS or CEA. The primary composite endpoint
was stroke, myocardial infarction (MI), or death from any
cause during the periprocedural period, or any ipsilateral
stroke within 4 years after randomization.
Results: Of the total cohort, 53% were symptomatic. Median
follow-up was 2.5 years. There was no significant difference
in the estimated 4-year rates of the primary endpoint
between the stenting and endarterectomy groups (7.2% and
6.8%, respectively; hazard ratio [HR] with stenting, 1.11;
95% confidence interval [CI], 0.81-1.51). Periprocedural
rates of individual components of the endpoints differed
between the stenting and endarterectomy groups, with
higher stroke rate with stenting (4.1% vs. 2.3%) and lower
incidence of MI (1.1% vs. 2.3%). The 4-year rate of stroke
or death was 6.4% with stenting and 4.7% with endarterec-
tomy. Similar trends were noted in symptomatic (8.0% and
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ventilatory threshold (VT), which is defined by the exercise
level at which Ve (minute ventilation) begins to increase
exponentially relative to the increase in VO2. VT is equiva-
lent to the anaerobic threshold. Exercise training has been
shown to increase VO2 at the VT.
6. Achievement of at least 85% of age-predicted maximal
heart rate is useful, but a relatively poor indicator of effort.
The respiratory exchange ratio (RER), defined as the ratio
between VCO2 and VO2, obtained from ventilatory expired
gas analysis, obviates the need to assess heart rate in deter-
mining subject effort. A peak RER of >1.10 is generally
considered an indication of excellent subject effort during
CPX, but it is not an indication to stop the test.
7. Ve can be assessed by evaluation of the rise in minute venti-
lation (Ve) relative to work rate or VCO2. The most widely
studied index of ventilatory efficiency is the Ve/VCO2 slope
(normal <30). Increasing values infer poor alveolar capillary
efficiency either from decreased cardiac output, increased dead
space, or pulmonary hypertension.
8. Pulse oximeters provide a general estimate of oxygenation
for safety monitoring and are used to identify trends during
exercise. A decrease of >5% in the pulse oximeter estimate of
arterial saturation during clinical CPX protocols is suggestive
of abnormal exercise-induced hypoxemia.
9. CPX appears most useful in the evaluation of patients with
heart failure and those with unexplained dyspnea. 
Summary written by: Melvyn Rubenfire, MD
Low-Dose Combination Therapy With Rosiglitazone
and Metformin to Prevent Type 2 Diabetes Mellitus
(CANOE trial): A Double-Blind Randomized
Controlled Study
Zinman B, Harris SB, Neuman J, et al.
Lancet 2010;376:103–111.
Study Question: What is the effect of low-dose combination
therapy with rosiglitazone and metformin on development
of type 2 diabetes? 
Methods: In this double-blind, randomized, controlled trial
undertaken in clinics in Canadian centers, 207 patients with
impaired glucose tolerance were randomly assigned to
receive combination rosiglitazone (2 mg) and metformin
(500 mg) twice daily or matching placebo for a median of
3.9 years.The primary outcome was time to development of
diabetes, measured by an oral glucose tolerance test or two
fasting plasma glucose values of 7.0 mmol/L or greater.
Results: A total of 103 participants were assigned to rosiglita-
zone and metformin, and 104 to placebo. Incident diabetes
occurred in significantly fewer individuals in the active treat-
ment group (n = 14 [14%]) than in the placebo group (n = 41
Conclusions: Patients taking ACE inhibitors have an
increased rate of AAA expansion. Use of other antihyper-
tensive medications, statins, and antiplatelet agents did not
appear to significantly affect AAA growth rates.
Perspective: I am concerned that the association of ACE
inhibitors and increased rate of AAA expansion may be a
result of confounding, that patients on ACE inhibitors had
higher and more difficult to control blood pressures than
those not on the drug. I believe that the key to reducing
expansion rates of aneurysms is excellent blood pressure con-
trol. If an ACE inhibitor in a patient with an AAA can
achieve this goal, then, in my opinion, it is worth the risk of
a possible slight increase in aneurysm expansion rate that
may be associated with ACE inhibitors.   
Summary written by: John E. Rectenwald, MD, MS
General Cardiology
Clinician’s Guide to Cardiopulmonary Exercise
Testing in Adults. A Scientific Statement From the
American Heart Association 
Balady GJ, Arena R, Sietsema K, et al.
Circulation 2010;122:191–225.
Perspective: The following are points to remember from this
American Heart Association Scientific Statement. 
1. Cardiopulmonary exercise testing (CPX), when performed
by experienced staff, offers a wealth of information beyond
standard exercise ECG testing that can assist in management
of complex cardiovascular and pulmonary disease.
2. Physical exercise capacity reflects the cardiovascular sys-
tem’s capacity to supply oxygen (O2) to the muscles and the
pulmonary system’s ability to clear carbon dioxide. The
increase in oxygen uptake is facilitated by an increase in car-
diac output (up to 6 times resting) and widening of the
arteriovenous oxygen difference (up to threefold resting).
3. Assessment of exercise capacity typically is performed on a
treadmill or stationary cycle ergometer. Untrained subjects
will usually terminate cycle exercise because of quadriceps
fatigue at 10-20% below their treadmill peak VO2, but
cycling is useful in the setting of obesity and orthopedic lim-
itations.
4. Maximal VO2 or peak VO2 is defined as when the VO2
plateaus between the last two stages of exercise. It may be
limited by orthopedic symptoms, cardiopulmonary subjective
symptoms, and inadequate effort. When estimated from the
work rate achieved rather than as directly measured VO2, it is
frequently expressed in metabolic equivalents (METs) (1
MET = 3.5 ml/kg/min). 
5. A widely used submaximal index of exercise capacity is the
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[39%]; p < 0.0001). Seventy (80%) patients in the treatment
group regressed to normal glucose tolerance compared with 52
(53%) in the placebo group (p = 0.0002). Insulin sensitivity
decreased by study end in the placebo group (median −1.24)
and remained unchanged with rosiglitazone and metformin
treatment (−0.39; p = 0.0006 between groups). The change
in β-cell function, as measured by the insulin secretion-sen-
sitivity index-2, did not differ between groups.
Conclusions: Low-dose combination therapy with rosiglita-
zone and metformin was highly effective in prevention of
type 2 diabetes in patients with impaired glucose tolerance.
Perspective: These results lend support to the use of low-dose
combination therapies as an effective means to manage
complex metabolic disorders. A comprehensive approach to
the global epidemic of type 2 diabetes should include
lifestyle intervention, focusing on obesity and physical activ-
ity, with the option of pharmacological intervention for the
primary prevention of diabetes as needed.  
Summary written by: Debabrata Mukherjee, MD
The Quality of Care Provided to Hospitalized
Patients at the End of Life 
Walling AM, Asch SM, Lorenz KA, et al.
Arch Intern Med 2010;170:1057–1063.
Study Question: What is the quality of end-of-life care among
hospitalized patients?
Methods: Medical records were abstracted using 16 Assessing
Care of Vulnerable Elders quality indicators. Patients who
died during hospitalization and were hospitalized for at least
3 days between April 2005 and April 2006 in a major uni-
versity medical center were included in the analysis.
Results: A total of 496 patients were included, of which 47%
were women. The mean age was 62 years, with 28% being 75
years or older. Primary reasons for hospitalization and death
included advanced cancer (21%) and end-stage disease (liver
16%, pulmonary 11%, renal 9%, and heart failure 6%).
Median hospital stay was 11 days, with 63% hospitalized for
10 or more days. Do not resuscitate (DNR) orders were pres-
ent in 84% of patients, with 28% of orders written on the day
of death. Of the 359 patients receiving mechanical ventilation,
46% had ventilator withdrawn prior to death. Family meetings
were documented in 55% of patients. Timely documentation
of discussion about patient preferences on admission occurred
less than 50% of the time. Only 18% of patients had advance
directives in their medical record. Only 29% of patients
undergoing withdrawal of mechanical ventilation had dyspnea
assessments documented in their charts.
Conclusions: Quality of end-of-life care, as documented in
medical charts, can be improved. Advance directives, pallia-
tive care plans, and assessment of symptoms such as pain
and dyspnea are important components of end-of-life care.
Perspective: Cardiovascular disease is a leading cause of death.
End-of-life care for patients with heart disease, in particular
heart failure, is an increasingly common part of hospital man-
agement. Yet training in end-of-life care is often not a
component of cardiovascular training. Further study of the
quality of care related to end-of-life care is needed.  
Summary written by: Elizabeth A. Jackson, MD
Mitral Regurgitation due to Degenerative 
Mitral-Valve Disease 
Foster E.
N Engl J Med 2010;363:156–165. 
Study Question: Degenerative mitral valve disease is the most
common form of organic mitral valve disease in the United
States and other developed countries. Mitral valve prolapse
is the most common functional abnormality associated with
degenerative mitral valve disease, and is associated with both
leaflet redundancy and chordal elongation.
The following are points to remember about this article:
1: Mitral regurgitation can complicate degenerative mitral
valve disease due to leaflet malcoaptation or rupture of elon-
gated chordae resulting in partial leaflet flail.
2: Chronic volume overload caused by gradually progressive
mitral regurgitation is well tolerated for an extended period,
with left atrial dilation mitigating high left atrial pressure, and
left ventricular dilation allowing normal forward cardiac out-
put mediated by high stroke volume. Eventually, left
ventricular systolic function occurs.
3: Clinical risks associated with degenerative mitral valve dis-
ease and mitral regurgitation include heart failure, atrial
fibrillation, and death. The risk of sudden death probably is
very low in the absence of symptoms, atrial fibrillation, or left
ventricular systolic dysfunction.
4: The mainstay of diagnostic evaluation lies with echocar-
diographic imaging, which allows for description of the
underlying mechanism and severity of mitral regurgitation,
and guides intervention. Transesophageal and three-dimen-
sional echocardiography can be useful adjunctive tools for
the assessment of mitral valve anatomy.  
5: There is no proven medical therapy for the treatment of
chronic mitral regurgitation caused by degenerative valve
disease.
6: Clinical outcomes are less favorable if surgery is per-
formed after the onset of left ventricular systolic dysfunction
or symptoms. The onset of atrial fibrillation is associated
with poor outcomes without surgical management of under-
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tolic (128.1 vs. 112.0 ml) and stroke volume (83.7 vs. 72.9
ml), and a trend toward increased peak ventricular filling
rate (79.4 vs. 60.5). 
Conclusions: Rosiglitazone increased peripheral edema, but
had no pernicious effects on CV performance or cardiac
function, with modest improvement in selected cMRI meas-
ures. Changes in indirect markers of plasma volume suggest
expansion with rosiglitazone.
Perspective: Data suggest that the TZDs may cause plasma
volume expansion via effects on renal sodium handling.
While it is reassuring that there are no direct negative CV
effects from TZDs, the increase in plasma volume and BNP,
as seen in this elegant study, is associated with an increased
risk of heart failure in both persons with a decrease in systolic
function and those with diastolic heart failure in the setting
of normal left ventricular ejection fraction.  
Summary written by: Melvyn Rubenfire, MD
Prospective Study of Obstructive Sleep Apnea and
Incident Coronary Heart Disease and Heart
Failure. The Sleep Heart Health Study
Gottlieb DJ, Yenokyan G, Newman AB, et al.
Circulation 2010;122:352–360.
Study Question: Is obstructive sleep apnea (OSA) associated
with the development of cardiac disease?
Methods: This was a prospective epidemiologic study of sub-
jects ≥40 years of age, free of coronary heart disease (CHD)
and heart failure (HF) at baseline. All subjects underwent in-
home polysonography, and the apnea-hypopnea index (AHI)
was calculated. Incident CHD was defined as myocardial
infarction, revascularization, or CHD death following
polysonography. Incident HF was defined as the first occur-
rence of HF during the follow-up period.
Results: There were 4,422 subjects (56% women) followed for
a mean of 8.7 years. Twenty-four percent of men and 11% of
women had moderate or worse OSA (AHI >14) on baseline
polysonography. In women, there was no association between
the AHI and the development of incident CHD or HF. The
AHI predicted the development of incident HF in men
(adjusted hazard ratio, 1.13 [1.02, 1.26] per 10 units of AHI),
but was only predictive of CHD development in men who
were ≤70 years of age (adjusted hazard ratio, 1.1 [1.00-1.21]
per 10 AHI units). 
Conclusions: OSA may be associated with the development of
HF in men ≥40 years old. Its association with the develop-
ment of CHD is less clear.
Perspective: It is not definitively known if OSA is an inde-
pendent risk factor for the development of CHD or HF.
Unfortunately, this study fails to shed significant light on
lying severe mitral regurgitation.
7: Results of mitral valve repair are highly dependent on the
anatomy of the valve and experience of the surgeon.
Prolapse or flail limited to the middle scallop of the poste-
rior mitral valve leaflet (P2) typically is thought to be most
readily amenable to successful mitral valve repair.
8: Current American College of Cardiology/American Heart
Association indications for surgical intervention for chronic
severe mitral regurgitation are symptoms (class I), left ven-
tricular systolic dysfunction (ejection fraction ≤60%, class I)
or dilation (systolic diameter ≥40 mm, class I), pulmonary
artery hypertension or new-onset atrial fibrillation (class
IIa), or mitral valve repair in an asymptomatic patient with
no other surgical indication (class IIa).
Summary written by: David S. Bach, MD
Heart Failure/Transplant
Randomized Comparison of the Effects of
Rosiglitazone vs. Placebo on Peak Integrated
Cardiovascular Performance, Cardiac Structure,
and Function 
McGuire DK, Abdullah SM, See R, et al.
Eur Heart J 2010;Jul 2:[Epub ahead of print]. 
Study Question: The thiazolidinedione (TZD) drugs rosiglita-
zone and pioglitazone for type 2 diabetes mellitus (T2DM)
cause peripheral edema and incident or worsening heart fail-
ure. What is the effect of rosiglitazone on cardiovascular
performance and cardiac function?
Methods: A total of 150 T2DM patients with cardiovascular
disease (CVD) or ≥1 other CVD risk factor were randomized
to receive rosiglitazone versus placebo for 6 months. The pri-
mary outcome was peak oxygen uptake indexed to fat-free
mass (VO2peak–FFM) during maximum exercise. A subset of
102 subjects underwent cardiac magnetic resonance imaging
(cMRI).
Results: A total of 108 subjects completed the study, includ-
ing 75 in the cMRI substudy. Mean age was 56 years; 41%
were women. Mean body mass index was 34.1 kg/m2 and
mean duration of T2DM was 9 years including 40% treated
with insulin. The prevalence of hypertension and hyperlipi-
demia were each 75%, 35% had prior CVD, and 17% were
smokers. No significant differences were observed in mean
VO2peak–FFM between rosiglitazone and placebo (26.1 ±
7.0 vs. 27.6 ± 6.6 ml/kg-FFM/min). Compared with
placebo, the rosiglitazone group had an increase in B-type
natriuretic peptide (BNP), weight, and lower hematocrit (38
vs. 41%) and more peripheral edema (53.7 vs. 33.3%). In the
cMRI substudy, the rosiglitazone group had larger end-dias-
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the query. A major limitation of the study is a vague defini-
tion of HF without a clearly mandated imaging or
standardized New York Heart Association functional class
assessment at follow-up. The reader is not provided infor-
mation on ejection fraction or diastology assessment at
baseline or at follow-up, and individuals with subclinical
(stage B) HF may have been missed.  
Summary written by: Jennifer Cowger, MD
Predicting Survival in Pulmonary Arterial
Hypertension. Insights From the Registry to
Evaluate Early and Long-Term Pulmonary Arterial
Hypertension Disease Management (REVEAL)
Benza RL, Miller DP, Gomberg-Maitland M, et al.
Circulation 2010;122:164–172.
Study Question: Factors that determine survival in pulmonary
arterial hypertension (PAH) drive clinical management. Can
an effective quantitative survival prediction tool be estab-
lished for research and clinical use?
Methods: Data from 2,716 patients with PAH enrolled con-
secutively in the US Registry to Evaluate Early and
Long-Term PAH Disease Management (REVEAL) were
analyzed to assess predictors of 1-year survival. Independent
prognosticators of survival were used to derive a multivari-
able, weighted risk formula for clinical use.
Results: Mean age was 50.4 years; 79% were women; 13.5%
were newly diagnosed and the remainder previously diag-
nosed; 49.4% had idiopathic or familial PAH; the remainder
had associated PH including 23.9% connective tissue disease
(CTD), 11.8% congenital heart disease, 5.1% portal hyperten-
sion, 4.9% drugs/toxins, and other 5%. The modified New
York Heart Association/World Health Organization func-
tional class (FC) distribution: I = 8.5%, II = 37.8%, III = 48%,
and IV = 5.5%. PAH therapies included prostacyclin analogs
in 1,092 (41.6%), endothelin receptor antagonists in 1,231
(46.9%), and phosphodiesterase-5 inhibitors in 1,301 (49.6%)
patients. A total of 1,087 (40.0%) and 687 (26.2%) patients
received combination PAH therapies or an intravenous
prostacyclin analog, respectively. One-year survival from the
date of enrollment was 91.0%. Variables independently associ-
ated with increased mortality included pulmonary vascular
resistance >32 Wood units (hazard ratio [HR], 4.1), PAH
associated with portal hypertension (HR, 3.6), FC IV (HR,
3.1), men >60 years of age (HR, 2.2), and family history of
PAH (HR, 2.2). Renal insufficiency, PAH associated with
CTD, FC III, mean right atrial pressure, resting systolic
blood pressure and heart rate, 6-minute walk distance, brain
natriuretic peptide, percent predicted carbon monoxide diffus-
ing capacity, and pericardial effusion on echocardiogram all
predicted mortality.
Conclusions: Key predictors of survival based on a PAH
patient’s most recent evaluation were used to develop a con-
temporary prognostic equation. Use of this tool may allow
the individualization and optimization of therapeutic strate-
gies. Serial follow-up and reassessment are warranted.
Perspective: The strength of the REVEAL registry is the size
of the cohort and that 54 geographically diverse community
and university PAH specialty care facilities in the United
States participated. It is particularly interesting that the equa-
tion may be used at the time of diagnosis or at any time
during a patient’s first year course. I suspect there will be a
considerable modification of the formula for predicting
longer-term follow-up.  
Summary written by: Melvyn Rubenfire, MD
Prevention/Vascular
Bicycle Riding, Walking, and Weight Gain in
Premenopausal Women
Lusk AC, Mekary RA, Feskanich D, Willett WC.
Arch Intern Med 2010;170:1050–1056.
Study Question: Does bike riding prevent weight gain over time
in women?
Methods: Data from the Nurses’ Health Study II (NHS II)
were used for the present analysis. NHS II is a prospective
study of 116,608 US women, ages 25–42 years at baseline.
The current study included women who were premenopausal
through 2005. Subjects reported their physical activity includ-
ing duration, walking pace, and other types of activities.
Activities over the past week and 7-day activity diaries were
used to determine physical activities. Self-reported sedentary
activities such as television watching were also reported. The
primary outcome of interest was weight change between 1989
and 2005.
Results: A total of 18,414 women were included. At baseline,
39% of subjects walked briskly and only 1.2% bicycled for
more than 30 minutes/day. A 30-minute/day increase in activ-
ity between 1989 and 2005 was associated with less weight
gain; for brisk walking (−1.81 kg), for bicycling (−1.59 kg),
and for other activities (−1.45 kg). In contrast, slow walking
was not associated with less weight gain (+0.06 kg).
Compared to nonbikers, women who initially reported no bik-
ing (in 1989) with an increase to 5 minutes/day or more in
2005 gained less weight (−0.74 kg). Normal-weight women
who bicycled more than 4 hours/week in 2005 had a lower
odds of gaining more than 5% of their baseline body weight
(odds ratio [OR], 0.74) compared with those who reported no
bicycling. The odds of gaining 5% or more of their baseline
body weight for overweight and obese women were also lower
with biking 4 hours/week (OR, 0.54).
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Conclusions: Biking is similar to brisk walking in terms of
prevention of weight gain over time, including among over-
weight and obese women.
Perspective: For overweight and obese women who may have
difficulty with brisk walking, biking offers an alternative
method to prevention of increased weight gain over time.
Clinicians should encourage patients to increase physical
activities by discussing specific activities that fit with the
patient’s preferences and capabilities.  
Summary written by: Elizabeth A. Jackson, MD
A Frequent Variant in the ABCA1 Gene Is
Associated With Increased Coronary Heart Disease
Risk and a Better Response to Statin Treatment in
Familial Hypercholesterolemia Patients
Versmissen J, Oosterveer DM, Yazdanpanah M, et al.
Eur Heart J 2010;Jul 1:[Epub ahead of print].
Study Question: Does a polymorphism in the ABCA1 gene
affect coronary artery disease (CAD) risk and response to
statin treatment?
Methods: A total of 1,686 familial hypercholesterolemia (FH)
patients without a history of coronary heart disease (CHD)
were analyzed for a statin-ABCA1 C69T polymorphism
interaction by comparing treated and untreated patients. A
Cox proportional hazard model adjusted for sex, birth year,
and smoking was used. 
Results: In untreated patients, the TT genotype was associ-
ated with 1.7 times higher CHD risk than the CC genotype
(p = 0.02). Conversely, in statin-treated FH patients, CHD
risk in TT individuals was not increased (p = 0.2). Formal
testing confirmed this interaction (p = 0.03). High-density
lipoprotein (HDL) cholesterol levels were significantly more
raised in statin-treated patients with the TT than with the
CC genotype (two-way ANOVA, p = 0.045). 
Conclusions: In untreated FH patients, the TT genotype of the
ABCA1 C69T polymorphism was associated with increased
CHD risk. However, in statin-treated patients, CHD risk
was no longer significantly different between genotypes, at
least partially explained by a higher rise in HDL cholesterol
levels during statin treatment in TT individuals.
Perspective: The study shows that a variant in the promoter
region of ABCA1 is associated with baseline CAD risk, but
no differences in HDL levels. However, HDL levels appear
more responsive to statin treatment in subjects with the TT
genotype, and this may attenuate the underlying CAD risk
associated with this polymorphism. Along with other gene
variants, certain genotypes may be predictive of clinical
response to statin treatment. A greater understanding of the
underlying mechanisms responsible for the effects of these
polymorphisms, as well as additional confirmatory clinical
studies, will be useful.  
Summary written by: Daniel T. Eitzman, MD
A School-Based Intervention for Diabetes Risk
Reduction
The HEALTHY Study Group.
N Engl J Med 2010;Jun 27:[Epub ahead of print].
Study Question: Does a school-based intervention reduce risk
for diabetes among middle-school students? 
Methods: The HEALTHY Study Group used a cluster study
design, which randomized 42 schools to either a multi-com-
ponent school-based intervention or a control group
(assessment only). Schools were included from seven field sites
and children of lower socioeconomic status were oversamples
because they are at high risk for diabetes. Students enrolled in
6th grade in fall 2006 were eligible. The intervention consisted
of nutrition, physical activity, behavioral knowledge and skills,
and communications and social marketing. 
Results: A total of 4,603 students, mean age 11.3 years (52.7%
girls) were included. A trend toward decreases in the primary
outcome, prevalence of overweight and obesity, was observed
in both the intervention and control group, with no statistical
difference between the groups. However, greater reductions in
BMI z score, percentage of students with waist circumferences
over the 90th percentile, fasting insulin levels (p = 0.04), and
prevalence of obesity (p = 0.05) were observed in the interven-
tion group. Similar findings were observed for students in the
85th percentile for BMI at baseline.
Conclusions: A school-based intervention among high-risk mid-
dle school students can reduce various indexes of adiposity.
Perspective: This large-scale study of middle-school children at
risk for diabetes suggests that a school-based intervention can
improve health by reducing factors associated with adiposity
and diabetes. Long-term follow-up to examine rates of dia-
betes in these groups will add to these current findings.  
Summary written by: Elizabeth A. Jackson, MD
Tight Blood Pressure Control and Cardiovascular
Outcomes Among Hypertensive Patients With
Diabetes and Coronary Artery Disease
Cooper-DeHoff RM, Gong Y, Handberg EM, et al.
JAMA 2010;304:61–68.
Study Question: Does tight blood pressure (BP) control reduce
cardiovascular (CV) outcomes among patient with diabetes
and coronary artery disease (CAD)? 
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Methods: Data from the International Verapamil SR-
Trandolapril (INVEST) trial were used for this analysis. An
observational subgroup of 6,400 participants (from the 22,576
INVEST subjects) who were 50 years or older, had diabetes,
and had CAD were recruited between September 1997 and
December 2000, from 862 sites in 14 countries. Subjects
received first-line treatment of either a calcium antagonist or
beta-blocker followed by an angiotensin-converting enzyme
inhibitor, a diuretic, or both to achieve a systolic BP of <130
mm Hg and a diastolic BP of <85 mm Hg. Patients were cate-
gorized by control into three groups: tight control <130 mm
Hg, usual control 130 to <140 mm Hg, and uncontrolled ≥140
mm Hg. The primary outcome included all-cause mortality,
nonfatal myocardial infarction, or nonfatal stroke.
Results: A total of 6,400 subjects were included (mean age 66
years, 54% women), of which 35.2% had tight BP control,
30.8% had usual BP control, and 34% had uncontrolled sys-
tolic BP. Over 16,893 patient-years of follow-up,
cardiovascular outcomes were experienced in 286 (12.7%) sub-
jects who had tight BP control, 249 (12.6%) who had usual
BP control, and 431 (19.8%) who had uncontrolled BP.
Subjects in the usual control group had fewer CV disease
(CVD) events, as compared to those with uncontrolled BP
(12.6% vs. 9.8%). No significant difference was observed in
CVD event rates for those in the usual BP control group com-
pared to those in the tight BP control group (12.6% vs.
12.7%). Regarding all-cause mortality, the event rate was
11.0% in the tight control versus 10.2% in the usual control
group. Over the extended follow-up period (through 2008),
all-cause mortality was higher among the tightly controlled
compared to the usual control group (22.8% vs. 21.8%).
Conclusions: Tight control of BP among patients with CAD
and diabetes was not associated with fewer CV events com-
pared with usual control.
Perspective: This important study suggests that BP control
among patients with CAD and diabetes should be <140 mm
Hg; however, tight control under 130 mm Hg does not pro-
vide added benefit.  
Summary written by: Elizabeth A. Jackson, MD
HDL Cholesterol and Residual Risk of First
Cardiovascular Events After Treatment With Potent
Statin Therapy: An Analysis From the JUPITER Trial
Ridker PM, Genest J, Boekholdt SM, et al.
Lancet 2010;376:333–339.
Study Question: What is the association between high-density
lipoprotein cholesterol (HDL-C) concentrations and occur-
rence of cardiovascular events when low-density lipoprotein
cholesterol (LDL-C) concentrations are reduced to the very
low ranges with high-dose statin treatment?  
Methods: Participants in the JUPITER trial were adults with-
out diabetes or previous cardiovascular disease, and had
baseline concentrations of LDL-C <3.37 mmol/L and high-
sensitivity C-reactive protein of 2 mg/L or more. Participants
were randomly allocated to receive rosuvastatin 20 mg per day
or placebo, with participants and adjudicators masked to
treatment assignment. In the present analysis, the investiga-
tors divided the participants into quartiles of HDL-C or
apolipoprotein A1, and sought evidence of association
between these quartiles and the JUPITER trial primary end-
point of first nonfatal myocardial infarction or stroke,
hospitalization for unstable angina, arterial revascularization,
or cardiovascular death.
Results: For 17,802 patients in the JUPITER trial, rosuvas-
tatin 20 mg per day reduced the incidence of the primary
endpoint by 44% (p < 0.0001). In 8,901 (50%) patients given
placebo (who had a median on-treatment LDL-C concentra-
tion of 2.80 mmol/L, HDL-C concentrations were inversely
related to vascular risk both at baseline (p = 0.0039) and on-
treatment (p = 0.0047). By contrast, among the 8,900 (50%)
patients given rosuvastatin 20 mg (who had a median on-
treatment LDL-C concentration of 1.42 mmol/L), no
significant relationships were noted between quartiles of
HDL-C concentration and vascular risk either at baseline (p
= 0.82) or on-treatment (p = 0.97). Their analyses for
apolipoprotein A1 showed an equivalent strong relation to
frequency of primary outcomes in the placebo group, but little
association in the rosuvastatin group.
Conclusions: HDL-C concentrations are not predictive of
residual vascular risk among patients treated with potent
statin therapy who attain very low concentrations of LDL-C.
Perspective: These data and recent secondary prevention data
from the TNT and PROVE IT trials provide little evidence
to support the hypotheses that HDL-C levels predict risk of
vascular events in the setting of high-dose statin therapy.
These data, however, should not dissuade clinicians from
measurement of HDL-C concentration as part of an initial
cardiovascular risk assessment. Randomized trials will be
needed to definitively test the role of potent HDL-raising
therapies in the statin era of reducing cardiovascular disease
events.  
Summary written by: Debabrata Mukherjee, MD
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